bevacizumab zirconium Zr-89

Bevacizumab zirconium Zr-89 is a radioimmunoconjugate composed of the recombinant humanized monoclonal antibody bevacizumab labeled with the radioisotope zirconium Zr 89. This agent is primarily used as an investigational imaging agent for positron emission tomography (PET) to visualize and quantify vascular endothelial growth factor A (VEGF-A) expression in tumors. The antibody moiety targets and binds to VEGF-A, allowing for noninvasive assessment of tumor angiogenesis and potentially aiding in patient selection for antiangiogenic therapies. Bevacizumab zirconium Zr-89 has been studied in clinical trials involving neuroendocrine tumors, diffuse intrinsic pontine glioma, metastatic renal cell carcinoma, and neurofibromatosis type 2[1][2][3][4][5][6]. It is not approved as a therapeutic but serves as a molecular imaging tool.

Other names

zirconium Zr 89-bevacizumab89Zr-bevacizumab